February 14th, 2012
•Dopamine replacement pharmacotherapy using L-DOPA is the most commonly used symptomatic treatment of Parkinson’s disease, but is accompanied by side effects including involuntary abnormal movements, termed dyskinesia 1. Here, a protocol for MALDI imaging mass spectrometry is presented that detects changes in rat brain neuropeptide levels related to dyskinesia.
Tags
Related Videos
Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
Skin Punch Biopsy Explant Culture for Derivation of Primary Human Fibroblasts
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
Imaging Metals in Brain Tissue by Laser Ablation - Inductively Coupled Plasma - Mass Spectrometry (LA-ICP-MS)
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved